TCGA-22-5481-01A-31R-1949-07
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
- age_years
- 72
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.650
- E2F_TARGETS+0.630
- MYC_TARGETS_V1+0.570
- G2M_CHECKPOINT+0.520
- DNA_REPAIR+0.360
- OXIDATIVE_PHOSPHORYLATION+0.280
- SPERMATOGENESIS+0.230
- MITOTIC_SPINDLE+0.210
- UNFOLDED_PROTEIN_RESPONSE+0.070
- PEROXISOME+0.060
Top 10 suppressed
- TGF_BETA_SIGNALING-0.520
- TNFA_SIGNALING_VIA_NFKB-0.510
- ANGIOGENESIS-0.500
- INFLAMMATORY_RESPONSE-0.480
- ANDROGEN_RESPONSE-0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- UV_RESPONSE_DN-0.440
- NOTCH_SIGNALING-0.420
- PROTEIN_SECRETION-0.420
- KRAS_SIGNALING_UP-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-HN-A2NL-01A-11R-A18M-07 | — | E | 0.932 |
| 2 | SRR8518168 | — | E | 0.912 |
| 3 | 20030039.TNBC | — | E | 0.906 |
| 4 | SRR8518197 | — | E | 0.905 |
| 5 | SAMN03290897 | — | — | 0.904 |
| 6 | 504282dd-4fef-4f70-a709-6a545d00a263 | — | — | 0.897 |
| 7 | TCGA-85-A510-01A-11R-A26W-07 | — | cohortA3 | 0.897 |
| 8 | TCGA-38-4630-01A-01R-1206-07 | — | cohortMD1 | 0.896 |
| 9 | AUR-AG0N-TTM1-A-1-1-R-A743-41 | — | E | 0.894 |
| 10 | BS_TZVFR600 | medulloblastoma | — | 0.894 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.650 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.630 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.570 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.520 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.030 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |